FISH for MYC amplification and anti-MYC immunohistochemistry: Useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations

Journal of Cutaneous Pathology

Volumn 39, Issue 2, 2012, Pages 234-242

  Fernandez, Anthony P ^a   Sun, Yang ^a   Tubbs, Raymond R ^a   Goldblum, John R ^a   Billings, Steven D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atypical vascular proliferation; FISH; Lymphedema associated angiosarcoma; MYC; Post radiation angiosarcoma

Indexed keywords

MYC PROTEIN; MYC PROTEIN, HUMAN;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; CELL NUCLEUS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SECOND CANCER; VASCULAR DISEASE;

ADULT; AGED; CELL NUCLEUS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMANGIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENE PROTEINS C-MYC; VASCULAR DISEASES;

EID: 84859265647     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2011.01843.x     Document Type: Article

References (27)

1. Billings SD, McKenney JK, Folpe AL, Hardacre MC, Weiss SW. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol 2004; 28: 781.
2. Fodor J, Orosz Z, Szabo E, et al. Angiosarcoma after conservation treatment for breast carcinoma: our experience and a review of the literature. J Am Acad Dermatol 2006; 54: 499.
3. Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol 1994; 102: 757.
4. Brenn T, Fletcher CDM. Radiationassociated cutaneous atypical vascular lesions and angiosarcoma. Am J Surg Pathol 2005; 29: 983.
5. Patton KT, Deyrup AT, Weiss SW. Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. Am J Surg Pathol 2008; 32: 943.
6. Weaver J, Billings SD. Postradiation cutaneous vascular tumors of the breast: a review. Semin Diagn Pathol 2009; 26: 141.
7. Mattoch IW, Robbins JB, Kempson RL, Kohler S. Post-radiotherapy vascular proliferations in mammary skin: a clinicopathologic study of 11 cases. J Am Acad Dermatol 2007; 57: 126.
8. Manner J, Radlwimmer B, Hohenberger P, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 2010; 176: 34.
9. Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR. Consistent MYC and FLT4 gene amplification in radiationinduced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer 2011; 50: 25.
10. Mentzel T, Schildhaus H-U, Palmedo G, Butner R, Kutzner H Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol 2011. [E-pub ahead of print; DOI:10.1038/modpathol.2011.134]
11. Clarke M, Collins R, Darby S, et al. Early breast cancer trialists' Collaborative Group: effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087.
12. Pass H, Vicini FA, Kestin LL. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breastconserving therapy at a single institution. Cancer 2004; 101: 713.
13. Cabioglu N, Hunt KK, Buchholz TA. Improving local control with breastconserving therapy: a 27-year singleinstitution experience. Cancer 2005; 104: 20.
14. West JG, Qureshi A, West JE, et al. Risk of angiosarcoma following breast conservation: a clinical alert. Breast J 2005; 11: 115.
15. Gengler C, Coindre JM, Leroux A, et al. Vascular proliferations of the skin after radiation therapy for breast cancer: clinicaopathologic analysis of a series in favor of a benign process: a study from the French SarcomaGroup. Cancer 2007; 109: 1584.
16. Sener SF, Milos S, Feldman JL, et al. The spectrum of vascular lesions in the mammary skin, including angiosarcoma, after breast conservation treatment for breast cancer. J Am Coll Surg 2001; 193: 22.
17. O'Hara CD, Nascimento AG. Endothelial lesions of soft tissues: a review of reactive and neoplastic entities with emphasis on low-grade malignant ("borderline") vascular tumors. Adv Anat Pathol 2003; 10: 69.
18. Gearhart J, Pashos EE, Prasad MK. Pluripotency Redeux - advances in stem-cell research. N Engl J Med 2007; 357: 1469.
19. Cotterman R, Jin VX, Krig SR, et al. NMYC regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 2008; 68: 9654.
20. Kretzner L, Blackwood EM, Eisenman RN. Myc and Max proteins possess distinct transcriptional activities. Nature 1992; 359: 426.
21. Hamlyn PH, Rabbitts TH. Translocation joins MYC and immunoglobulin gamma 1 genes in a Burkitt lymphoma revealing a third exon in the MYC oncogene. Nature 1983; 304: 135.
22. Taub R, Kirsch I, Morton C, et al. Translocation of the MYC gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 1982; 79: 7837.
23. Hann SR, Dixit M, Sears RC, Sealy L. The alternatively initiated MYC proteins differentially regulate transcription through a noncanonicalDNA- binding site.Genes Dev 1994; 8: 2441.
24. Liu J, Martin HJ, Liao G, Hayward SD. The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates MYC. J Virol 2007; 81: 10451.
25. Tarkkanen M, Larramendy ML, Bohling T, et al. Malignant fibrous histiocytoma of bone: analysis of genomic imbalances by comparative genomic hybridisation and MYC expression by immunohistochemistry. Eur J Cancer 2006; 42: 1172.
26. Morrison C, Radmacher M, Mohammed N, et al. MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J Clin Oncol 2005; 23: 9369.
27. Marampon F, Ciccarelli C, Zani BM. Downregulation of MYC following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in nonmuscle- derived human tumors. Mol Cancer 2006; 5: 31.